期刊文献+
共找到6篇文章
< 1 >
每页显示 20 50 100
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion 被引量:7
1
作者 Yi Sun Min Wei +10 位作者 Shan-Cheng Ren Rui Chen Wei-Dong Xu fu-bo wang Ji Lu Jian Shen Yong-Wei Yu Jian-Guo Hou Chuan-Liang Xu Jiao-Ti Huang Ying-Hao Sun 《Asian Journal of Andrology》 SCIE CAS CSCD 2014年第2期319-324,I0012,共7页
SETDB1 has been established as an oncogene in a number of human carcinomas. The present study was to evaluate the expression of SETDB1 in prostate cancer (PCa) tissues and cells and to preliminarily investigate the ... SETDB1 has been established as an oncogene in a number of human carcinomas. The present study was to evaluate the expression of SETDB1 in prostate cancer (PCa) tissues and cells and to preliminarily investigate the role of SETDB1 in prostate tumorigenesis in vitro. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were used to detect the expression of SETDB1 in PCa tissues, adjacent normal tissues, benign prostatic hyperplasia (BPH) tissues, PCa cell lines and normal prostate epithelial cells. The results suggested that SETDB1 was upregulated in human PCa tissues compared with normal tissues at the mRNA and protein levels. The role of SETDB1 in proliferation was analyzed with cell counting kit-8, colony-forming efficiency and flow cytometry assays. The results indicated that downregulation of SETDB1 by siRNA inhibited PCa cell growth, and induced GO/G1 cell cycle arrest. The PCa cell migration and invasion decreased by silcencing SETDBt which were assessed by using in vitro scratch and transwell invasion assay respectively. Our data suggested that SETDB1 is overexpressed in human PCa. Silencing SETDB1 inhibited PCa cell proliferation, migration and invasion. 展开更多
关键词 EPIGENOMICS histone methyltransferases prostate cancer (PCa) SETDB1
下载PDF
Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml^-1 被引量:13
2
作者 Rui Chen Li-Qun Zhou +25 位作者 Xiao-Bing Cai Li-Ping Xie Yi-Ran Huang Da-Lin He Xu Gao Chuan-Liang Xu Qiang Ding Qiang wei Chang-Jun Yin Shan-Cheng Ren fu-bo wang Ye Tian Zhong-Quan Sun Qiang Fu Lu-Lin Ma Jun-Hua Zheng Zhang-Qun Ye Ding-Wei Ye Dan-Feng Xu Jian-Quan Hou Ke-Xin Xu Jian-Lin Yuan Xin Gao Chun-Xiao Liu Tie-Jun Pan Ying-Hao Sun 《Asian Journal of Andrology》 SCIE CAS CSCD 2015年第6期1017-1021,I0012,共6页
Percent free prostatic-specific antigen (%fPSA) has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml^-1, however, it remains controversial whether %fPSA is... Percent free prostatic-specific antigen (%fPSA) has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml^-1, however, it remains controversial whether %fPSA is effective in PSA range of 10.1-20.0 ng ml^-1 in both Chinese and Western population. In this study, the diagnostic performance of %fPSA and serum PSA in predicting prostate cancer (PCa) and high-grade PCa (HGPCa) was analyzed in a multi-center biopsy cohort of 5915 consecutive Chinese patients who underwent prostate biopsy in 22 hospitals across China from January 1, 2010 to December 31, 2013. The indication for biopsy was PSA〉4.0 ng ml^-1 or/and suspicious digital rectal examination. Total and free serum PSA determinations were performed by three types of electrochemiluminescence immunoassays with recalibration to the World Health Organization standards. The diagnostics accuracy of PSA, %fPSA and %fPSA in combination with PSA (%fPSA + PSA) was determined by the area under the receivers operating characteristic curve (AUC). %fPSA was more effective than PSA in men aged ≥60 years old. The AUC was 0.584 and 0.635 in men aged ≥60 years old with a PSA of 4.0-10.0 ng ml^-1 and 10.1-20.0 ng ml^-1, respectively. The AUC of %fPSA was superior to that of PSA in predicting HGPCa in patients ≥60 years old in these two PSA range. Our results indicated that %fPSA is both statistically effective and clinical applicable to predict prostate biopsy outcome in Chinese patients aged ≥60 years old with a PSA of 4.0-10.0 ng ml^-1 and 10.1-20.0 ng ml^-1. 展开更多
关键词 Chinese population diagnosis percent free prostate-specific antigen prostate cancer prostate carcinoma tumor antigen prostate-specific antigen
原文传递
PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium 被引量:9
3
作者 Zi-Jian Song Jin-Ke Qian +7 位作者 Yue Yang Han-Xiao Wu Mao-Yu wang Si-Yuan Jiang fu-bo wang Wei Zhang Rui Chen Chinese Prostate Cancer Consortium 《Asian Journal of Andrology》 SCIE CAS CSCD 2021年第3期300-305,共6页
We performed this study to investigate the diagnostic performance of prostate-specific antigen density(PSAD)in a multicenter cohort of the Chinese Prostate Cancer Consortium.Outpatients with prostate-specific antigen(... We performed this study to investigate the diagnostic performance of prostate-specific antigen density(PSAD)in a multicenter cohort of the Chinese Prostate Cancer Consortium.Outpatients with prostate-specific antigen(PSA)levels≥4.0 ng ml^(-1) regardless of digital rectal examination(DRE)results or PSA levels<4.0 ng ml^(-1)and abnormal DRE results were included from 18 large referral hospitals in China.The diagnostic performance of PSAD and the sensitivity and specificity for the diagnosis of prostate cancer(PCa)and high-grade prostate cancer(HGPCa)at different cutoff values were evaluated.A total of 5220 patients were included in the study,and 2014(38.6%)of them were diagnosed with PCa.In patients with PSA levels ranging from 4.0 to 10.0 ng ml^(-1),PSAD was associated with PCa and HGPCa in both univariate(odds ratio[OR]=45.15,P<0.0001 and OR=25.38,P<0.0001,respectively)and multivariate analyses(OR=52.55,P<0.0001 and OR=26.05,P<0.0001,respectively).The areas under the receiver operating characteristic curves(AUCs)of PSAD in predicting PCa and HGPCa were 0.627 and 0.630,respectively.With the PSAD cutoff of 0.10 ng ml^(-2),we obtained a sensitivity of 88.7%for PCa,and nearly all(89.9%)HGPCa cases could be detected and biopsies could be avoided in 20.2%of the patients(359/1776 cases).Among these patients who avoided biopsies,only 30 cases had HGPCa.We recommend 0.10 ng ml^(-2) as the proper cutoff value of PSAD,which will obtain a sensitivity of nearly 90%for both PCa and HGPCa.The results of this study should be validated in prospective,population-based multicenter studies. 展开更多
关键词 CHINESE early detection of cancer prostate cancer prostate-specific antigen prostate-specific antigen density
原文传递
Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy 被引量:10
4
作者 fu-bo wang Rui Chen +9 位作者 Shan-Cheng Ren Xiao-Lei Shi Ya-Sheng Zhu Wei Zhang Tai-Le Jing Chao Zhang Xu Gao Jian-Guo Hou Chuan-Liang Xu Ying-Hao Sun 《Asian Journal of Andrology》 SCIE CAS CSCD 2017年第2期238-243,共6页
Prostate cancer antigen 3 (PCA3) is a biomarker for diagnosing prostate cancer (PCa) identified in the Caucasian population. We evaluated the effectiveness of urinary PCA3 in predicting the biopsy result in 500 me... Prostate cancer antigen 3 (PCA3) is a biomarker for diagnosing prostate cancer (PCa) identified in the Caucasian population. We evaluated the effectiveness of urinary PCA3 in predicting the biopsy result in 500 men undergoing initial prostate biopsy. The predictive power of the PCA3 score was evaluated by the area under receiver operating characteristic (ROC) curve (AUC) and by decision curve analysis. PCA3 score sufficed to discriminate positive from negative prostate biopsy results but was not correlated with the aggressiveness of PCa. The ROC analysis showed a higher AUC for the PCA3 score than %fPSA (0.750 vs 0.622, P = 0.046) in patients with a PSA of 4.0-10.0 ng ml-I, but the PCA3-based model is not significantly better than the base model. Decision curve analysis indicates the PCA3-based model was superior to the base model with a higher net benefit for almost all threshold probabilities, especially the threshold probabilities of 25%-40% in patients with a PSA of 4.0-10.0 ng ml-1. However, the AUC of the PCA3 score (0.712) is not superior to %fPSA (0.698) or PSAD (0.773) in patients with a PSA 〉10.0 ng ml-1. Our results confirmed that the RT-PCR-based PCA3 test moderately improved diagnostic accuracy in Chinese patients undergoing first prostate biopsy with a PSA of 4.0-10.0 ng ml-1. 展开更多
关键词 DIAGNOSIS long noncoding RNA prostate cancer antigen 3 prostatic neoplasms
原文传递
Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review 被引量:4
5
作者 De-Pei Kong Rui Chen +6 位作者 Chun-Lei Zhang Wei Zhang Guang-An Xiao fu-bo wang Na Ta Xu Gao Ying-Hao Sun 《Asian Journal of Andrology》 SCIE CAS CSCD 2020年第2期200-207,共8页
Fusion between the transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog(TMPRSS2-ERG fusion)is a common genetic alteration in prostate cancer among Western populations and has been sugg... Fusion between the transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog(TMPRSS2-ERG fusion)is a common genetic alteration in prostate cancer among Western populations and has been suggested as playing a role in tumorigenesis and progression of prostate cancer.However,the prevalence of TMPRSS2-ERG fusion differs among different ethnic groups,and contradictory results have been reported in Asian patients.We aim to evaluate the prevalence and significance of TMPRSS2-ERG fusion as a molecular subtyping and prognosis indicator of prostate cancer in Asians.We identified the fusion status in 669 samples from prostate biopsy and radical prostatectomy by fluorescence in situ hybridization and/or immunohistochemistry in China.We examined the association of TMPRSS2-ERG fusion with clinicopathological characteristics and biochemical recurrence by Chi-square test and Kaplan–Meier analysis.Finally,a systematic review was performed to investigate the positive rate of the fusion in Asian prostate cancer patients.McNemar’s test was employed to compare the positive rates of TMPRSS2-ERG fusion detected using different methods.The positive rates of TMPRSS2-ERG fusion were 16%in our samples and 27%in Asian patients.In our samples,9.4%and 19.3%of cases were recognized as fusion positive by fluorescence in situ hybridization and immunohistochemistry,respectively.No significant association between the fusion and clinical parameters was observed.TMPRSS2-ERG fusion is not a frequent genomic alteration among Asian prostate cancer patients and has limited significance in clinical practices in China.Besides ethnic difference,detection methods potentially influence the results showing a positive rate of TMPRSS2-ERG fusion. 展开更多
关键词 ASIAN Chinese PROSTATE cancer systematic review TMPRSS2-ERG
原文传递
MAGI-2 downregulation:a potential predictor of tumor progression and early recurrenee in Han Chinese patients with prostate cancer
6
作者 Zhi Cao Jin Ji +6 位作者 fu-bo wang Chen Kong Huan Xu Ya-Long Xu Xi Chen Yong-Wei Yu Ying-Hao Sun 《Asian Journal of Andrology》 SCIE CAS CSCD 2020年第6期616-622,共7页
Membrane-associated guanylate kinase(MAGUK)family protein MAGUK invert 2(MAGI-2)has been demonstrated to be involved in the tumorigenic mechanism of prostate cancer.The objective of this study was to investigate the e... Membrane-associated guanylate kinase(MAGUK)family protein MAGUK invert 2(MAGI-2)has been demonstrated to be involved in the tumorigenic mechanism of prostate cancer.The objective of this study was to investigate the expression of MAGI・2 at mRNA and protein levels.The prog no stic value of MAGI-2 in Han Chin ese patie nts with prostate cancer was also investigated.The expression data of MAGI・2 were assessed through database retrieval,analysis of sequencing data from our group,and tissue immunohistochemistry using digital scoring system(H・score).The clinical,pathological,and follow-up data were collected.The expression of MAGI-2 in prostate tumor tissues and prostate normal tissues was evaluated and compared.MAGI-2 expression was associated with clinical parameters including tumor stage,lymph node status,Gleason score,PSA level,and biochemical recurrenee of prostate cancer.The relative expression of MAGI-2 mRNA was lower in the tumor tissue in The Cancer Genome Atlas(TCGA)database and sequencing data(P<0.001).There was no difference in MAGI-2 protein expression between tumor and normal tissues in tissue microarray(TMA)results.MAGI-2 expression was associated with pathological tumor stage(P=0.02),Gleason score(P=0.05),and preoperation prostate-specific antigen(PSA;P=0.04).A positive correlation was identified between MAGI-2 and phosphatase and tensin homolog deleted on chromosome 10(PTEN)expressions through the analysis of TCGA and TMA data(P<0.0001).Patients with higher MAGI-2 expression had longer biochemical recurrence-free survival in the univariate analysis(P=0.005),which in dicates an optimal prog no stic value of MAGI-2 in Han Chin ese patie nts with prostate can cer.I n con elusion,MAGI-2 expressi on gradually decreases with tumor progression,and can be used as a predictor of tumor recurrence in Chinese patients. 展开更多
关键词 biochemical recurrenee Chinese patients MAGI-2 prostate cancer tissue microarray
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部